Deflazacort, a synthetic glucocorticoid related to prednisolone, is the active ingredient in Deflazacort tablets. It is prescribed for inflammatory, autoimmune and neuromuscular conditions when corticosteroid treatment is clinically appropriate. Its anti-inflammatory and immunosuppressive action reduces excessive immune activity.
Deflazacort belongs to the glucocorticoid class of corticosteroids. The active ingredient is deflazacort, a synthetic oxazoline derivative of prednisolone. The tablet is intended for oral use.
Deflazacort may be prescribed when inflammation or abnormal immune activity contributes to tissue damage. The appropriate indication depends on the diagnosis and the prescriber’s treatment plan.
Clinical uses can include:
The role in Duchenne muscular dystrophy differs from the short courses sometimes used for acute inflammation. Treatment can extend over a long period, so clinicians monitor muscle function, weight, growth, blood pressure, glucose, bone health and adrenal activity.
Deflazacort can reduce inflammation, yet it also suppresses normal immune responses. A person taking it may have fewer inflammatory symptoms while remaining vulnerable to infection or experiencing corticosteroid-related metabolic effects. The Duchenne muscular dystrophy evidence base and regulatory indication information describe benefits alongside these monitoring needs [2].
Glucocorticoids enter cells and influence gene transcription through intracellular glucocorticoid receptors. This reduces the production of inflammatory mediators and limits the activity of several immune cells. Deflazacort therefore has both anti-inflammatory and immunosuppressive properties.
After absorption, deflazacort is converted to an active metabolite. The active steroid-receptor complex affects inflammatory gene expression in tissues and peripheral blood mononuclear cells. This reduces signalling from lymphocytes and other immune cells involved in chronic inflammation.
The effect develops through changes in protein production, so Deflazacort is not a rapid painkiller. It works by suppressing the biological processes that sustain inflammation, swelling and immune-mediated tissue injury. The pharmacological classification and receptor activity are described in regulatory information for deflazacort [1].
NOT for you if a prescriber has identified a contraindication, an untreated serious infection makes immunosuppression unsafe, or required monitoring cannot be arranged.
Deflazacort can cause corticosteroid adverse effects, with risk increasing alongside dose, treatment duration and individual susceptibility. Short courses may cause fewer cumulative complications than prolonged therapy, while long-term treatment requires structured monitoring.
Possible effects include:
Children and adolescents require attention to height, weight, puberty and bone development. Deflazacort may have a smaller effect on growth rate than some prednisolone regimens in selected studies, but growth suppression remains possible. The same applies to bone health: a relative advantage in calcium handling does not eliminate fracture risk.
A persistent sore throat, painful urination, worsening cough or unusual fever can indicate infection requiring prompt assessment because corticosteroids may reduce visible inflammation. Black stools, vomiting blood, severe abdominal pain, marked weakness, confusion, sudden visual symptoms or severe mood changes require urgent medical attention. The FDA prescribing information describes the recognised risks of systemic deflazacort treatment .
One practical detail is easy to miss: steroid-related insomnia can be worse when the dose is taken late in the day. If the prescribed schedule allows morning administration, taking the tablet earlier may reduce sleep disruption.
Another detail concerns infection. A normal temperature does not always exclude infection during corticosteroid therapy, especially when other symptoms are present.
Deflazacort belongs to the glucocorticoid class of corticosteroids. The active ingredient is deflazacort, a synthetic oxazoline derivative of prednisolone. The tablet is intended for oral use.
The dose of Deflazacort is decided individually, taking age, other medicines and health conditions into account. The prescribed dose may change when the disease improves, during an acute flare or when treatment is being tapered.
Do not alter the regimen when starting an antibiotic, antifungal, anticonvulsant or herbal product. Some medicines change steroid exposure, and others add to the risks of infection, stomach irritation, mood changes or reduced immunity.
Deflazacort, prednisolone, prednisone, methylprednisolone and betamethasone all act through glucocorticoid receptors, but their potency, duration and mineralocorticoid activity differ. These differences affect the dose selected and the adverse effects monitored.
| Corticosteroid | Relative clinical profile | Common prescribing consideration |
|---|---|---|
| Deflazacort | Related to prednisolone; often selected where its metabolic profile is considered suitable | Dose conversion requires clinical judgement |
| Prednisone or prednisolone | Established systemic corticosteroids with broad clinical use | Monitoring includes glucose, blood pressure, weight, infection and bone health |
| Methylprednisolone or betamethasone | More potent glucocorticoid activity per milligram than prednisolone | Small dose differences can produce substantial changes in exposure |
Published comparisons describe deflazacort as having a prednisolone-equivalent potency commonly estimated within a range of about 0.69 to 0.89, depending on the clinical context and conversion method. Deflazacort may show fewer effects on urinary calcium handling, glucose metabolism or growth in some patient groups, though these findings do not remove the risks associated with systemic corticosteroids.
A lower rate of a specific adverse effect does not make the treatment risk-free. Prednisone or prednisolone may remain preferable when clinicians have greater experience with a particular disease, need a familiar conversion protocol or are following an established local guideline. Methylprednisolone and betamethasone may be chosen when a higher glucocorticoid potency or a particular route is required.
The choice is clinical rather than cosmetic. A person should not substitute one corticosteroid for another without a new prescribed regimen, because equivalent doses vary and abrupt changes can affect adrenal function.
Several avoidable errors reduce treatment control or increase risk:
One overlooked issue is vaccination planning. Some immunisations may require special timing or an individual assessment during immunosuppressive corticosteroid therapy. Tell the vaccination provider about current treatment before an appointment.
In clinical practice, doctors usually judge Deflazacort by disease control and functional outcomes rather than symptom relief alone. For Duchenne muscular dystrophy, useful measures can include strength, mobility, respiratory function, growth and daily activity. For inflammatory disease, clinicians may follow pain, swelling, organ function, blood tests and relapse frequency.
A physician will also weigh the steroid benefit against cumulative exposure. A lower impact on some metabolic or bone measures may support the choice of Deflazacort for a specific patient, yet monitoring remains necessary. The MHRA and EMA approach systemic corticosteroids as medicines requiring indication-specific prescribing and risk assessment.
The practical goal is the lowest dose that controls the condition, followed by a planned reduction when clinically appropriate. Tapering too quickly can trigger disease relapse or adrenal symptoms; remaining on an unchanged dose without review can increase cumulative adverse effects.
The MHRA’s general oral-medicine safety principles support taking tablets exactly as prescribed, while the product’s physical design determines whether splitting is appropriate. Do not crush or chew a tablet unless the prescribing team has confirmed that this is suitable for the specific product. Splitting can also make dose measurement unreliable when a precise taper is required. The relevant medicine information and tablet instructions should be confirmed before altering the dosage form, with the MHRA remaining the UK regulatory authority in 2026.
Before starting, disclose diabetes, high blood pressure, osteoporosis, glaucoma, cataracts, stomach ulcer, liver disease, kidney disease, mental-health conditions, previous steroid reactions and recent infections. Mention all medicines, including anticoagulants, anticonvulsants, antifungals, non-steroidal anti-inflammatory drugs and vaccines. The WHO’s corticosteroid safety principles recognise infection risk, metabolic effects and adrenal suppression as clinically relevant concerns; these concerns remain relevant in 2026. This discussion is also important when Deflazacort is being started after another corticosteroid.
Children and adolescents may receive Deflazacort for selected conditions, including Duchenne muscular dystrophy, when a specialist considers the benefits appropriate. Treatment requires attention to growth, weight, puberty, bone health, blood pressure and infection symptoms. FDA regulatory information from 2017 includes paediatric use considerations, while the Duchenne muscular dystrophy evidence base supports specialist monitoring rather than unsupervised use. The dose is individual and should not be calculated by simply copying an adult regimen.
Take the missed tablet when remembered unless the next scheduled dose is near. In that situation, skip the missed dose and resume the normal schedule; do not double the next dose. The advice is more urgent for people receiving long-term treatment, because repeated missed doses can complicate disease control and steroid withdrawal. The EMA’s medicine-safety framework supports following the prescribed schedule and obtaining individual instructions when vomiting, illness or repeated missed doses occur; this advice remains applicable in 2026.
Seek urgent medical help for severe breathing difficulty, facial swelling, collapse, severe confusion, suicidal thoughts, sudden vision loss, black stools, vomiting blood or signs of severe infection. Do not independently stop long-term Deflazacort just because a serious symptom appears; emergency clinicians need to know the steroid history and may decide how treatment should be managed. The 2024 NICE guidance on adrenal insufficiency and acute illness highlights the danger of inadequate steroid coverage during physiological stress. Persistent fever, severe weakness, fainting or repeated vomiting also warrants prompt assessment.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
My joint swelling settled gradually rather than overnight. I noticed a bigger appetite and some difficulty sleeping during the first week, so taking the tablet earlier helped. The improvement was useful, but I needed follow-up blood tests.
The treatment reduced the stiffness enough for me to move around the house more easily. I also developed bruising on my hands and felt more irritable. My dose was reduced in stages, and stopping suddenly was never presented as an option.
Deflazacort helped during a difficult flare, and my symptoms were less disruptive after the first couple of weeks. I disliked the increased appetite and restless sleep. The main benefit was being able to return to ordinary activities, while the drawbacks needed regular monitoring.
